


## WHAT IS CLAIMED IS:

1. A method of treating atherosclerotic plaque rupture comprising administering to a mammal in need of such treatment, a safe and effective amount of a compound having a structure according to Formula (I):



wherein

A is alkyl, heteroalkyl, aryl or heteroaryl, substituted or unsubstituted ;

R<sub>1</sub> is NHOR<sub>2</sub>, where R<sub>2</sub> is hydrogen or alkyl;

W is one or more of hydrogen, lower alkyl, or an alkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

Y is independently one or more of hydroxy, SR<sub>3</sub>, SOR<sub>4</sub>, SO<sub>2</sub>R<sub>8</sub>, alkoxy, or amino, wherein the amino is of formula NR<sub>6</sub>R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR<sub>3</sub>, SO<sub>2</sub>R<sub>8</sub>, COR<sub>9</sub>, CSR<sub>10</sub>, and PO(R<sub>11</sub>)<sub>2</sub>;

R<sub>3</sub> is hydrogen, alkyl, aryl, or heteroaryl;

R<sub>4</sub> is alkyl, aryl, or heteroaryl;

each R<sub>8</sub> is independently chosen from group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylaryl amino;

R<sub>9</sub> is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylaryl amino;

R<sub>10</sub> is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylaryl amino;

R<sub>11</sub> is alkyl, aryl, heteroaryl, or heteroalkyl;


Z is hydrogen, hydroxy, alkyl, or an alkylene or heteroalkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

n is 1; and

provided that (i) when any one or more of  $R_3$ ,  $R_4$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ , W, Y or Z is itself, or together with another moiety forms, a heterocyclic moiety, that heterocyclic moiety is furan, and (ii) when W or Z is an alkylene or heteroalkylene bridge that forms a second ring fused to the ring depicted in Formula (I), that second ring does not include the ring carbon atom depicted in Formula (I) that is bonded to  $C(=O)-R_1$ ; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

2. The method of Claim 1, wherein the compound is of structure:



wherein

A is aryl or heteroaryl, substituted or unsubstituted ;

$R_1$  is  $NHOR_2$ , where  $R_2$  is hydrogen or alkyl;

W is one or more of hydrogen or lower alkyl;

Y is independently one or more of hydroxy,  $SR_3$ ,  $SOR_4$ ,  $SO_2R_8$ , alkoxy, or amino, wherein the amino is of formula  $NR_6R_7$ , wherein  $R_6$  and  $R_7$  are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl,  $OR_3$ ,  $SO_2R_8$ ,  $COR_9$ ,  $CSR_{10}$  and  $PO(R_{11})_2$ ;

$R_3$  is hydrogen, alkyl, aryl, or heteroaryl;

$R_4$  is alkyl, aryl, or heteroaryl;

each  $R_8$  is independently chosen from the group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

$R_9$  is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R<sub>10</sub> is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino, or alkylarylamino;

R<sub>11</sub> is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen; and

n is 1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

3. The method of Claim 2, wherein the compound is selected from the group consisting of:

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*S*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*S*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-methoxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-benzothiazolyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-(2-mercaptobenzo-thiazolyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-[(1*N*)-methyl-2-mercaptoimidazolyl]-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-[(1*N*)-methyl-2-mercaptoimidazolyl]-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-phenoxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(4-benzyloxy)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(3-*N*-phenylamino)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-mercaptophenylpyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(4-methoxyphenyl-thioloxyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(3-methoxy-mercaptophenyl)-pyrrolidine;


(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(n-hexylamino)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-thiopyrrolidine;  
 (±)-(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(3*S*)-phenylpyrrolidine;  
 (1*N*)-(4-Methylphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
 (1*N*)-(3,4-Dimethoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
 (1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
 (1*N*)-4-*n*Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
 (1*N*)-(4-*n*Butoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
 (1*N*)-(4-*n*Butoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-  
 benzothiazolyl)-pyrrolidine;  
 (1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-  
 benzothiazolyl)-pyrrolidine;  
 (±)-(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-5-pyrrolidinone;  
 (1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4,4*R*)-hydroxy-ethylpyrrolidine;  
 and  
 (1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-morpholinopyrrolidine.

4. The method according to Claim 3, wherein the compound is selected from the group consisting of:

(1*N*)-4-Phenoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido- (4*R*)-hydroxypyrrolidine;  
 (1*N*)-4-*n*-Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
 (1*N*)-4-*n*-Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine; and  
 (1*N*)-4-*n*-Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-morpholinopyrrolidine.

5. A composition comprising: (a) a stent; (b) a drug releasing polymer; and (c) a safe and effective amount of a compound of Formula (I):



wherein

A is alkyl, heteroalkyl, aryl or heteroaryl, substituted or unsubstituted ;

R<sub>1</sub> is NHOR<sub>2</sub>, where R<sub>2</sub> is hydrogen or alkyl;

W is one or more of hydrogen, lower alkyl, or an alkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

Y is independently one or more of hydroxy, SR<sub>3</sub>, SOR<sub>4</sub>, SO<sub>2</sub>R<sub>8</sub>, alkoxy, or amino, wherein the amino is of formula NR<sub>6</sub>,R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR<sub>3</sub>, SO<sub>2</sub>R<sub>8</sub>, COR<sub>9</sub>, CSR<sub>10</sub>, and PO(R<sub>11</sub>)<sub>2</sub>;

R<sub>3</sub> is hydrogen, alkyl, aryl, or heteroaryl;

R<sub>4</sub> is alkyl, aryl, or heteroaryl;

each R<sub>8</sub> is independently chosen from group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylaminio;

R<sub>9</sub> is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylaminio;

R<sub>10</sub> is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylarylaminio;

R<sub>11</sub> is alkyl, aryl, heteroaryl, or heteroalkyl;


Z is hydrogen, hydroxy, alkyl, or an alkylene or heteroalkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

n is 1; and

provided that (i) when any one or more of R<sub>3</sub>, R<sub>4</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, W, Y or Z is itself, or together with another moiety forms, a heterocyclic moiety, that heterocyclic moiety is furan, and (ii) when W or Z is an alkylene or heteroalkylene bridge that forms a second ring fused to the ring depicted in Formula (I), that second ring does not include the ring carbon atom depicted in Formula (I) that is bonded to C(=O)-R<sub>1</sub>; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

6. The composition of Claim 5, wherein the compound is of structure:



(I)

wherein

A is aryl or heteroaryl, substituted or unsubstituted ;

R<sub>1</sub> is NHOR<sub>2</sub>, where R<sub>2</sub> is hydrogen or alkyl;

W is one or more of hydrogen or lower alkyl;

Y is independently one or more of hydroxy, SR<sub>3</sub>, SOR<sub>4</sub>, SO<sub>2</sub>R<sub>8</sub>, alkoxy, or amino, wherein the amino is of formula NR<sub>6</sub>,R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR<sub>3</sub>, SO<sub>2</sub>R<sub>8</sub>, COR<sub>9</sub>, CSR<sub>10</sub> and PO(R<sub>11</sub>)<sub>2</sub>;

R<sub>3</sub> is hydrogen, alkyl, aryl, or heteroaryl;

R<sub>4</sub> is alkyl, aryl, or heteroaryl;

each R<sub>8</sub> is independently chosen from the group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino;

R<sub>9</sub> is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylarylamino;

R<sub>10</sub> is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino, or alkylarylamino;

R<sub>11</sub> is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen; and

n is 1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

7. The composition of Claim 6, wherein the compound is selected from the group consisting of:

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*S*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*S*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-methoxypyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-  
benzothiazolyl)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-(2-mercaptobenzo-  
thiazolyl)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-[(1*N*)-methyl-2-  
mercaptoimidazolyl]-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-[(1*N*)-methyl-2-  
mercaptoimidazolyl]-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-phenoxypyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(4-benzyloxy)-  
phenoxypyrrolidine;  
(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(3-*N*-phenylamino)-  
phenoxypyrrolidine;  
(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-phenoxypyrrolidine;  
(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-mercaptophenylpyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(4-methoxyphenyl-  
thioloxyl)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(3-methoxy-  
mercaptophenyl)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(n-hexylamino)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-thiopyrrolidine;  
(±)-(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(3*S*)-phenylpyrrolidine;  
(1*N*)-(4-Methylphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
(1*N*)-(3,4-Dimethoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-4-nButoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-(4-nButoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
(1*N*)-(4-nButoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-  
benzothiazolyl)-pyrrolidine;  
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-  
benzothiazolyl)-pyrrolidine;  
(±)-(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-5-pyrrolidinone;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4,4*R*)-hydroxy-ethylpyrrolidine;  
and

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-morpholinopyrrolidine.


8. The composition of Claim 7, wherein the compound is selected from the group consisting of:

(1*N*)-Phenoxyphenylsulfonyl-(2*R*)-carbomethoxy-(4*R*)-hydroxypyrrolidine;

(1*N*)-4-<sup>n</sup>Butoxyphenylsulfonamido-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine; and

(1*N*)-4-<sup>n</sup>Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine.

9 A method of treating restenosis comprising administering to a mammal in need of such treatment, a safe and effective amount of a compound of having a structure according to Formula (I):



(I)

wherein

A is alkyl, heteroalkyl, aryl or heteroaryl, substituted or unsubstituted ;

R<sub>1</sub> is NHOR<sub>2</sub>, where R<sub>2</sub> is hydrogen or alkyl;

W is one or more of hydrogen, lower alkyl, or an alkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

Y is independently one or more of hydroxy, SR<sub>3</sub>, SOR<sub>4</sub>, SO<sub>2</sub>R<sub>8</sub>, alkoxy, or amino, wherein the amino is of formula NR<sub>6</sub>,R<sub>7</sub>, wherein R<sub>6</sub> and R<sub>7</sub> are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl, OR<sub>3</sub>, SO<sub>2</sub>R<sub>8</sub>, COR<sub>9</sub>, CSR<sub>10</sub>, and PO(R<sub>11</sub>)<sub>2</sub>;

R<sub>3</sub> is hydrogen, alkyl, aryl, or heteroaryl;

R<sub>4</sub> is alkyl, aryl, or heteroaryl;



each  $R_8$  is independently chosen from group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylaryl amino;

$R_9$  is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylaryl amino;

$R_{10}$  is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino or alkylaryl amino;

$R_{11}$  is alkyl, aryl, heteroaryl, or heteroalkyl;


Z is hydrogen, hydroxy, alkyl, or an alkylene or heteroalkylene bridge that forms a ring in addition to the ring depicted in Formula (I);

n is 1; and

provided that (i) when any one or more of  $R_3$ ,  $R_4$ ,  $R_8$ ,  $R_9$ ,  $R_{10}$ ,  $R_{11}$ , W, Y or Z is itself, or together with another moiety forms, a heterocyclic moiety, that heterocyclic moiety is furan, and (ii) when W or Z is an alkylene or heteroalkylene bridge that forms a second ring fused to the ring depicted in Formula (I), that second ring does not include the ring carbon atom depicted in Formula (I) that is bonded to  $C(=O)-R_1$ ; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

10. The method of Claim 9, wherein the compound is of structure:



wherein

A is aryl or heteroaryl, substituted or unsubstituted ;

$R_1$  is  $NHOR_2$ , where  $R_2$  is hydrogen or alkyl;

W is one or more of hydrogen or lower alkyl;

Y is independently one or more of hydroxy,  $SR_3$ ,  $SOR_4$ ,  $SO_2R_8$ , alkoxy, or amino, wherein the amino is of formula  $NR_6R_7$ , wherein  $R_6$  and  $R_7$  are independently chosen from hydrogen, alkyl, heteroalkyl, heteroaryl, aryl,  $OR_3$ ,  $SO_2R_8$ ,  $COR_9$ ,  $CSR_{10}$  and  $PO(R_{11})_2$ ;

R<sub>3</sub> is hydrogen, alkyl, aryl, or heteroaryl;

R<sub>4</sub> is alkyl, aryl, or heteroaryl;

each R<sub>8</sub> is independently chosen from the group consisting of alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino and alkylaryl amino;

R<sub>9</sub> is hydrogen, alkoxy, aryloxy, heteroaryloxy, alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino or alkylaryl amino;

R<sub>10</sub> is alkyl, aryl, heteroaryl, heteroalkyl, amino, alkylamino, dialkylamino, arylamino, diarylamino, or alkylaryl amino;

R<sub>11</sub> is alkyl, aryl, heteroaryl, or heteroalkyl;

Z is hydrogen; and

n is 1; or

an optical isomer, diastereomer or enantiomer for Formula (I), or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof.

11) The method of Claim 10, wherein the compound is selected from the group consisting of:

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*S*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*S*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-methoxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercapto-benzothiazolyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-(2-mercaptobenzo-thiazolyl)-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-[(1*N*)-methyl-2-mercaptoimidazol]-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-[(1*N*)-methyl-2-mercaptoimidazol]-pyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-phenoxypyrrolidine;

(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(4-benzyloxy)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(3-*N*-phenylamino)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-phenoxypyrrolidine;

(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-mercaptophenylpyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(4-methoxyphenylthioxy)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(3-methoxymercaptophenyl)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(n-hexylamino)-pyrrolidine;  
(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-thiopyrrolidine;  
(±)-(1*N*)-(4-Methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(3*S*)-phenylpyrrolidine;  
(1*N*)-(4-Methylphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
(1*N*)-(3,4-Dimethoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-4-nButoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-(4-nButoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine;  
(1*N*)-(4-nButoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercaptobenzothiazolyl)-pyrrolidine;  
(1*N*)-(2-Nitro-4-methoxyphenylsulfonyl)-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-(2-mercaptobenzothiazolyl)-pyrrolidine;  
(±)-(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-5-pyrrolidinone;  
(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4,4*R*)-hydroxy-ethylpyrrolidine;  
and  
(1*N*)-4-Methoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-morpholinopyrrolidine.

12. The method Claim 11, wherein the compound is selected from the group consisting of:

(1*N*)-4-Phenoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido- (4*R*)-hydroxypyrrolidine;  
(1*N*)-4-n-Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*R*)-hydroxypyrrolidine;  
(1*N*)-4-n-Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-hydroxypyrrolidine; and  
(1*N*)-4-n-Butoxyphenylsulfonyl-(2*R*)-*N*-hydroxycarboxamido-(4*S*)-morpholinopyrrolidine.